Cyclosporine a limits myocardial infarct size even when administered after onset of ischemia

Cardiovascular Research

Volumn 38, Issue 3, 1998, Pages 676-684

  Weinbrenner, Christof ^a,b   Liu, Guang S ^a   Downey, James M ^a   Cohen, Michael V ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cyclosporine A; FK 506; Infarct size; Ischemic preconditioning; L NAME; Nitric oxide; Phosphorylation; PP2B; Protein phosphatases

Indexed keywords

CYCLOSPORIN A; TACROLIMUS; CYCLOSPORIN; ENZYME INHIBITOR; IMMUNOSUPPRESSIVE AGENT; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PROTEIN KINASE (CALCIUM,CALMODULIN);

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPHOSPHORYLATION; DRUG EFFECT; DRUG MECHANISM; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT OUTCOME; ANIMAL; DRUG ANTAGONISM; FEMALE; HEART MUSCLE; HEART MUSCLE ISCHEMIA; MALE; PATHOLOGY; PERFUSION; RABBIT;

ANIMALS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CYCLOSPORINE; ENZYME INHIBITORS; FEMALE; IMMUNOSUPPRESSIVE AGENTS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PERFUSION; RABBITS; TACROLIMUS;

EID: 0032088501     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00064-9     Document Type: Article

References (64)

1. [1] Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-1136.
2. 1 adenosine receptors in rabbit heart. Circulation 1991;84:350-356.
3. 1-adrenergic mechanism. Circ Res 1993;73:656-670.
4. 1-Adrenergic agonists precondition rabbit ischemic myocardium independent of adenosine by direct activation of protein kinase C. Circ Res 1994;75:576-585.
5. [5] Wang P, Gallagher KP, Downey JM, Cohen MV. Pretreatment with endothelin-1 mimics ischemic preconditioning against infarction in isolated rabbit heart. J Mol Cell Cardiol 1996;28:579-588.
6. [6] Liu Y, Tsuchida A, Cohen MV, Downey JM. Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol 1995;27:883-892.
7. [7] Yao Z, Gross GJ. Acetylcholine mimics ischemic preconditioning via a glibenclamide-sensitive mechanism in dogs. Am J Physiol 1993;264:H2221-H2225.
8. [8] Thornton JD, Liu GS, Downey JM. Pretreatment with pertussis toxin blocks the protective effects of preconditioning: evidence for a G-protein mechanism. J Mol Cell Cardiol 1993;25:311-320.
9. [9] Goto M, Liu Y, Yang X-M, Ardell JL, Cohen MV, Downey JM. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 1995;77:611-621.
10. [10] Schultz JEJ, Rose E, Yao Z, Gross GJ. Evidence for the involvement of opioid receptors in ischemic preconditioning in rat hearts. Am J Physiol 1995;268:H2157-H2161.
11. [11] Ytrehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol 1994;266:H1145-H1152.
12. [12] Liu Y, Cohen MV, Downey JM. Chelerythrine, a highly selective protein kinase C inhibitor, blocks the antiinfarct effect of ischemic preconditioning in rabbit hearts. Cardiovasc Drugs Ther 1994;8:881-882.
13. [13] Speechly-Dick ME, Mocanu MM, Yellon DM. Protein kinase C: its role in ischemic preconditioning in the rat. Circ Res 1994;75:586-590.
14. [14] Ikonomidis JS, Shirai T, Weisel RD, Derylo B, Rao V, Whiteside CI, Mickle DAG, Li R-K. Preconditioning cultured human pediatric myocytes requires adenosine and protein kinase C. Am J Physiol 1997;272:H1220-H1230.
15. [15] Weinbrenner C, Liu G-S, Cohen MV, Downey JM. Phosphorylation of tyrosine 182 of p38 mitogen-activated protein kinase correlates with the protection of preconditioning in the rabbit heart. J Mol Cell Cardiol 1997;29:2383-2391.
16. + currents by protein kinase C and adenosine: implications for ischemic preconditioning. Circ Res 1996;78:443-454.
17. [17] Yang X-M, Sato H, Downey JM, Cohen MV. Protection of ischemic preconditioning is dependent upon a critical timing sequence of protein kinase C activation. J Mol Cell Cardiol 1997;29:991-999.
18. [18] Armstrong SC, Ganote CE. Effects of the protein phosphatase inhibitors okadaic acid and calyculin A on metabolically inhibited and ischaemic isolated myocytes. J Mol Cell Cardiol 1992;24:869-884.
19. [19] Armstrong SC, Hoover DB, Delacey MH, Ganote CE. Translocation of PKC, protein phosphatase inhibition and preconditioning of rabbit cardiomyocytes. J Mol Cell Cardiol 1996;28:1479-1492.
20. [20] Walsh AH, Cheng A, Honkanen RE. Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A. FEBS Lett 1997;416:230-234.
21. [21] Weinbrenner C, Baines CP, Liu G-S, Armstrong SC, Ganote CE, Walsh AH, Honkanen RE, Cohen MV, Downey JM. Fostriecin, an inhibitor of protein phosphatase 2A, limits myocardial infarct size even when administered after onset of ischemia. Circulation 1998; (in press).
22. [22] Armstrong SC, Kao R, Gao W, Shivell LC, Downey JM, Honkanen RE, Ganote CE. Comparison of in vitro preconditioning responses of isolated pig and rabbit cardiomyocytes: effects of a protein phosphatase inhibitor, fostriecin. J Mol Cell Cardiol 1997;29:3009-3024.
23. [23] Kahan BD. Cyclosporine. New Engl J Med 1989;321:1725-1738.
24. [24] Fruman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci USA 1992;89:3686-3690.
25. [25] Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992;357:695-697.
26. [26] Liu J, Farmer JD Jr., Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991;66:807-815.
27. [27] Griffiths EJ, Halestrap AP. Protection by cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol 1993;25:1461-1469.
28. [28] Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 1995;307:93-98.
29. 2+-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress. Biochem J 1988;255:357-360.
30. 1, a mycotoxin. Biochem Biophys Res Commun 1996;220:160-165.
31. [31] Duchen MR, McGuinness O, Brown LA, Crompton M. On the involvement of a cyclosporin A sensitive mitochondrial pore in myocardial reperfusion injury. Cardiovasc Res 1993;27:1790-1794.
32. [32] Massoudy P, Zahler S, Kupatt C, Reder E, Becker BF, Gerlach E. Cardioprotection by cyclosporine A in experimental ischemia and reperfusion - evidence for a nitric oxide-dependent mechanism mediated by endothelin. J Mol Cell Cardiol 1997;29:535-544.
33. [33] Gabauer I, Slezak J, Styk J, Ziegelhöffer A. Further assessment of the protective effect of calmodulin inhibitors against reperfusion injury after acute coronary occlusion in the dog. Can J Cardiol 1994;10:125-132.
34. [34] Stewart AA, Hemmings BA, Cohen P, Goris J, Merlevede W. The MgATP-dependent protein phosphatase and protein phosphatase 1 have identical substrate specificities. Eur J Biochem 1981;115:197-205.
35. [35] Ganapathi MK, Lee EYC. Dephosphorylation and inactivation of phosphorylase kinase: subunit specificity of rabbit skeletal muscle protein phosphatases. Arch Biochem Biophys 1984;233:19-31.
36. 2+-dependent, calmodulin-stimulated enzyme. Methods Enzymol 1988;159:409-416.
37. [37] Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
38. 1-selective adenosine analogues protects the heart against infarction. Circulation 1992;85:659-665.
39. [39] Wolf H, Hofmann F. Purification of myosin light chain kinase from bovine cardiac muscle. Proc Natl Acad Sci USA 1980;77:5852-5855.
40. 80). FEBS Lett 1982;137:80-84.
41. 2+/calmodulin-dependent protein phosphatase (2B) from rabbit skeletal muscle. Eur J Biochem 1983;132:289-295.
42. 2+ exchanger of heart sarcolemma is regulated by a phosphorylation-dephosphorylation process. Soc Gen Physiol Ser 1984;38:149-160.
43. [43] Zimmermann N, Gams E, Neumann J, Boknik P, Scholz H. Effects of cyclosporine on protein phosphorylation in the heart. Transplant Proc 1994;26:2875-2876.
44. 2+/calmodulin-dependent protein phosphatase and secretion in pancreatic acinar cells. J Biol Chem 1994;269:15111-15117.
45. [45] Klee CB, Krinks MH, Manalan AS, Cohen P, Stewart AA. Isolation and characterization of bovine brain calcineurin: a calmodulin-stimulated protein phosphatase. Methods Enzymol 1983;102:227-244.
46. [46] Wera S, Hemmings BA. Serine/threonine protein phosphatases. Biochem J 1995;311:17-29.
47. [47] Walsh CT, Zydowsky LD, McKeon FD. Cyclosporin A, the cyclophilin class of peptidylprolyl isomerases, and blockade of T cell signal transduction. J Biol Chem 1992;267:13115-13118.
48. [48] Griffiths EJ, Halestrap AP. Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immuno-suppressive and toxic effects of cyclosporin. Biochem J 1991;274:611-614.
49. [49] Taniguchi I, Taniguchi M, Kobayashi M, Onodera T, Seki S, Mochizuki S. Real time measurement of nitric oxide during ischemic preconditioning. J Mol Cell Cardiol 1997;29:A232. (Abstract).
50. [50] Bilinska M, Maczewski M, Berȩsewicz A. Donors of nitric oxide mimic effects of ischaemic preconditioning on reperfusion induced arrhythmias in isolated rat heart. Mol Cell Biochem 1996;160:265-271.
51. [51] Weselcouch EO, Baird AJ, Sleph P, Grover GJ. Inhibition of nitric oxide synthesis does not affect ischemic preconditioning in isolated perfused rat hearts. Am J Physiol 1995;268:H242-H249.
52. [52] Woolfson RG, Patel VC, Neild GH, Yellon DM. Inhibition of nitric oxide synthesis reduces infarct size by an adenosine-dependent mechanism. Circulation 1995;91:1545-1551.
53. [53] Bunchman TE, Brookshire CA. Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest 1991;88:310-314.
54. [54] Takeda Y, Yoneda T, Ito Y, Miyamori I, Takeda R. Stimulation of endothelin mRNA and secretion in human endothelial cells by FK 506. J Cardiovasc Pharmacol 1993;22:S310-S312. Suppl 8.
55. [55] Goodall T, Kind CN, Hammond TG. FK 506-induced endothelin release by cultured rat mesangial cells. J Cardiovasc Pharmacol 1995;26:S482-S485. Suppl 3.
56. [56] Brunner F, du Toit EF, Opie LH. Endothelin release during ischaemia and reperfusion of isolated perfused rat hearts. J Mol Cell Cardiol 1992;24:1291-1305.
57. [57] Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992;13:136-142.
58. 3 receptors: pharmacological properties, species differences and receptor functions. Trends Pharmacol Sci 1994;15:298-306.
59. [59] Wang P, Downey JM, Cohen MV. Mast cell degranulation does not contribute to ischemic preconditioning in isolated rabbit hearts. Basic Res Cardiol 1996;91:458-467.
60. [60] Maxwell MP, Hearse DJ, Yellon DM. Species variation in the coronary collateral circulation during regional myocardial ischaemia: a critical determinant of the rate of evolution and extent of myocardial infarction. Cardiovasc Res 1987;21:737-746.
61. [61] Cohen MV, Yang X-M, Liu Y, Snell KS, Downey JM. A new animal model of controlled coronary artery occlusion in conscious rabbits. Cardiovasc Res 1994;28:61-65.
62. [62] Goto M, Miura T, Iliodoromitis EK, O'Leary EL, Ishimoto R, Yellon DM, Iimura O. Adenosine infusion during early reperfusion failed to limit myocardial infarct size in a collateral deficient species. Cardiovasc Res 1991;25:943-949.
63. [63] Vander Heide RS, Reimer KA. Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs. Cardiovasc Res 1996;31:711-718.
64. [64] Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993;24:472-495.